[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd ADR (RHHBY)

Roche Holding Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 325,470,784
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,471 M
  • Annual Income, $ 15,546 M
  • EBIT $ 0 M
  • EBITDA $ 26,387 M
  • 60-Month Beta 0.50
  • Price/Sales 4.22
  • Price/Cash Flow 14.05
  • Price/Book 7.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.97 (1.92%)
  • Most Recent Dividend 0.972 on 03/13/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.2400 +3.76%
on 04/09/26
52.0000 -1.75%
on 04/22/26
+1.0100 (+2.02%)
since 04/08/26
3-Month
47.0500 +8.59%
on 03/20/26
60.8500 -16.04%
on 02/24/26
-6.6100 (-11.46%)
since 02/06/26
52-Week
35.0700 +45.68%
on 05/15/25
60.8500 -16.04%
on 02/24/26
+11.9800 (+30.63%)
since 05/08/25

Most Recent Stories

More News
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

New real-world data confirm Vabysmo’s potent retinal drying in wet AMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease...

RHHBY : 51.0900 (+1.00%)
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

‘All Eyes on DME’ campaign aims to educate and empower people impacted by or at-risk for diabetic macular edema (DME)—a serious, common and often overlooked eye condition ...

RHHBY : 51.0900 (+1.00%)
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis...

RHHBY : 51.0900 (+1.00%)
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) ...

RHHBY : 51.0900 (+1.00%)
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE) ...

RHHBY : 51.0900 (+1.00%)
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...

RHHBY : 51.0900 (+1.00%)
CCCC : 2.95 (-1.01%)
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets

PLEASANTON, Calif. , March 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas ® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test...

ROP : 343.32 (-2.59%)
RHHBY : 51.0900 (+1.00%)
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation

INDIANAPOLIS , March 18, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S . Food and Drug Administration (FDA) has categorized its Ionify® steroid assays...

ROG : 140.66 (+2.48%)
RHHBY : 51.0900 (+1.00%)
Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

BASEL, Switzerland , March 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark approval for its Elecsys ® Apolipoprotein E4 biomarker test...

ROG : 140.66 (+2.48%)
RHHBY : 51.0900 (+1.00%)
3 ETFs to Avoid as Oil Shock Hits Markets

With oil prices soaring near $100 per barrel, certain sectors are feeling more pain than others. Here are three ETFs to avoid amid oil's market roil.

LVMUY : 111.6000 (+0.37%)
TRIP : 10.45 (-6.95%)
TSLA : 428.35 (+4.02%)
SAP : 173.70 (-0.58%)
XLY : 120.20 (+0.27%)
JETS : 27.48 (-0.40%)
EXPE : 229.98 (-9.02%)
NVS : 146.03 (+0.44%)
VGK : 88.12 (+0.96%)
RHHBY : 51.0900 (+1.00%)
AMZN : 272.68 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 51.9967
2nd Resistance Point 51.5433
1st Resistance Point 51.3167
Last Price 51.0900
1st Support Level 50.6367
2nd Support Level 50.1833
3rd Support Level 49.9567

See More

52-Week High 60.8500
Last Price 51.0900
Fibonacci 61.8% 51.0020
Fibonacci 50% 47.9600
Fibonacci 38.2% 44.9180
52-Week Low 35.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.